Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine.

Byeong-Jae Lee Hyeok-Il Kwon Eun-Ha Kim Su-Jin Park Sang-Ho Lee Young Ki Choi Sang-Hyun Kim

Published in: Clinical and experimental vaccine research (2014)

Our results indicate that mOMV could be a promising vaccine adjuvant by itself and it could be used as a vaccine platform for development of various vaccine formulations to prepare future influenza pandemic.

Keyphrases

early stage
coronavirus disease
current status
single cell